{"name":"Autolus Therapeutics","slug":"autolus","ticker":"AUTL","exchange":"NASDAQ","domain":"autolus.com","description":"Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the","hq":"London, UK","founded":0,"employees":"752","ceo":"Christian Itin","sector":"Cell Therapy / Oncology","stockPrice":1.6,"stockChange":-0.11,"stockChangePercent":-6.43,"marketCap":"$426M","metrics":{"revenue":10120000,"revenueGrowth":496,"grossMargin":0,"rdSpend":117689000,"netIncome":-287528000,"cash":217450000,"dividendYield":0,"peRatio":-2.3,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Imfinzi patent cliff ($0.0B at risk)","drug":"Imfinzi","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Autolus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Autolus Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $44.1 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-04","type":"deal","headline":"Autolus Therapeutics Announces Collaboration with Gilead Sciences to Develop and Commercialize Autologous T-Cell Therapies","summary":"Autolus Therapeutics announced a collaboration with Gilead Sciences to develop and commercialize autologous T-cell therapies for the treatment of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Autolus Therapeutics Announces Positive Interim Results from Phase 1/2 Clinical Trial of Imfinzi in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","summary":"Autolus Therapeutics announced positive interim results from a Phase 1/2 clinical trial of imfinzi in relapsed or refractory B-cell non-Hodgkin lymphoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5GOEVXcDlHLXF1QlRrb1V0UUFndUlCNk1YVHFfS2E2QmxYdXJGVG1JVWw1VTYwcXhpcFJWYVJRSzVvUjZZeGlydFVRNE94OTBkdHdmM19wckZ3THMyRGfSAWNBVV95cUxPbkg5ZzYzMzlUd2pPUkNmR1BNTGtmaUlsWERmTWlJdFllQ3dXd1ZyVG9HU002ODNsTnlhVjBWU2kzQ2p3RUVmeGxfbnQ3RTNVNTVNUDRBTkpyNDI4akpLMzJyTWc?oc=5","date":"2026-03-31","type":"pipeline","source":"Bitget","summary":"Apellis Pharmaceuticals (APLS) Surges 135.4%: Can This Momentum Be Sustained? - Bitget","headline":"Apellis Pharmaceuticals (APLS) Surges 135.4%: Can This Momentum Be Sustained?","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-03","type":"earnings","source":"simplywall.st","summary":"The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26% - simplywall.st","headline":"The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-13","type":"trial","source":"simplywall.st","summary":"Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials - simplywall.st","headline":"Autolus Therapeutics (AUTL) Is Down 25.0% After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQR2FkZXM2MHZuWHJ1b2hub1RSQzVPWEpmdkJkWjgzQXFtYnI5VFNBR1pUNnhJY3hMWkg1eGthZW02T1NBLVpVWEIzd0J6WGdIQnZNWHpMZy11ZV9lMC11RWVQN3R2b0RjelJrWkhIQ002dklMcXhob3VZdlJlWWdZa2lySHlSRlZ1MjVzaEhlT1VITVVGdldEUkdnYnpBQzRuTDdnd0FzcksyWVNuTlJ0aUpaZDlUSEtGSjBGMV9TSHIyZS1DcktpaHNmT2JIR3JzVEN5TkVaOHE3bVhScmZQLWoyYlh1OXBPSVFZX0VSOG52RmYxVHFrSFB5OGdjNWVmbVdaajVqYmtraDdIRUx0NHB3?oc=5","date":"2025-12-29","type":"pipeline","source":"Benzinga","summary":"Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Mon - Benzinga","headline":"Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Mon","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"trial","source":"simplywall.st","summary":"A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data - simplywall.st","headline":"A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1BNGxZOFR6bno4YWZJUEFubVRTbUR6ejVZR3d4a1p0Z1VTZ21kaFYzdDg1YWliYVk3eU1FUWNwRlRIc2ptVzA1N1JsSmtsUGNpMHJIWlRPenlsb2JvZzd0cHBTVGsxTlotUWxKbWF6YXp0U1d3QnF5c3ZOOA?oc=5","date":"2025-11-10","type":"earnings","source":"Yahoo Finance","summary":"Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - Yahoo Finance","headline":"Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5TY3NuRnNUaVVXcXk2TGFXVmxYY2ZXSXJZYTBObWFMbUpQRGlWVWNlRWJxYTRmeFMtVjVsTTNyNVItMnNYdnhVNzF6UEg2bEZGUWdQTklpbTJfd3Zxd1ZLbWwwQ0NsNnVG?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Autolus Therapeutics (AUTL) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AUTL - MarketBeat","headline":"Autolus Therapeutics (AUTL) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AUTL","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQV1lDSlpzT2o4MTdTWnRXbS1HOVJ6aFdrREtiVGhqUWVKcFpoaHhTVnVMLTFwVENxWWRYWktlem1ldTNMbnczckJBV21jLTZfcXhGa2tnN2ZkR2NhbzV5T3F6LTc1V3ZHNXJaYUp2UEdGVW9IWGd5TU8zSmpabV9GcVl2c0ctZTJBZXIzZkNaSEthcTAxQjVMcHdyTXJYNTU4bV9SNnJWSEM0UjUwZkNyVWp4bVktUVprM1JqWUNB?oc=5","date":"2025-06-06","type":"trial","source":"Seeking Alpha","summary":"Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market (AUTL) - Seeking Alpha","headline":"Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market (AUTL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNbkVpZkIzWHJ0RnB0T1pEbGRtM2VnTmFtVXI0X21EcU1pcWtXbTc1TjlzNVo3WXRQT2pKTTR1Q1RPSkFIcW9FSUNHcmIyZklFVHhTZ01maGRhbTl3dTJaYnZvU3NjT3cxaGRMQ2ZVQWFscFhrbWhfYVBaa29FN0xqR2tzQmc?oc=5","date":"2025-04-28","type":"pipeline","source":"The Pharma Letter","summary":"MHRA backs Aucatzyl for lymphoblastic leukemia - The Pharma Letter","headline":"MHRA backs Aucatzyl for lymphoblastic leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQbnI4VjRpbzh4WnRIYTFpN09faUdObmIwYjE4azEtZ2JJY2o4a01EdzJFQnplSFVYb1dqVGFwSVY0cnZKaXNQbTNvYmZXcHc5a2tjUmdSUnhyM0l4aEVLS2ZjbmZua0diRkx4c2szcHBDOG1yTnZkYWNCYjlkU21XcWFRaw?oc=5","date":"2025-03-20","type":"pipeline","source":"StocksToTrade","summary":"Autolus Therapeutics Stock: Will The Tide Turn?​ - StocksToTrade","headline":"Autolus Therapeutics Stock: Will The Tide Turn?​","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQTU9XMWpRZEcxR0ZZTzJja25weDFQaVJBQm9sOVk3OTFweS1IeURkU2FfNUVUOEJEOHUxY3padkNYeFc3QXp2ZkJ2WkEweVExRXd0YnhwbWt1QW5Zc1hHLXFTdnBDQzVxbFh6bVJHTWZyVXJtclBoREpWN1gzeVgyYXl0Uy1Kdw?oc=5","date":"2024-12-30","type":"pipeline","source":"Yahoo Finance","summary":"Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance","headline":"Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFAzQS15cUxBSlc2SGZfbXdQcENpaUFCT2JWSkJCVzhldXY3NGRpXzJYMlhGYjVlNWhfRG1KUF9jN0g0UVRaNVBtRHo3dkJtSjlr?oc=5","date":"2024-02-09","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Imfinzi","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Novartis"],"therapeuticFocus":["Oncology","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":10120000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":10120000,"period":"2024-12-31"},{"value":1698000,"period":"2023-12-31"}],"grossProfit":-20981000,"grossProfitHistory":[{"period":"2025-12-31","value":-20981000},{"period":"2024-12-31","value":-1267000},{"period":"2023-12-31","value":1698000}],"rdSpend":117689000,"rdSpendHistory":[{"period":"2025-12-31","value":117689000},{"period":"2024-12-31","value":138436000},{"period":"2023-12-31","value":130481000},{"period":"2022-12-31","value":117354000}],"sgaSpend":131874000,"operatingIncome":-270544000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-270544000},{"period":"2024-12-31","value":-241426000},{"period":"2023-12-31","value":-175528000},{"period":"2022-12-31","value":-142893000}],"netIncome":-287528000,"netIncomeHistory":[{"period":"2025-12-31","value":-287528000},{"period":"2024-12-31","value":-220662000},{"period":"2023-12-31","value":-208383000},{"period":"2022-12-31","value":-148839000}],"eps":-1.08,"epsHistory":[{"period":"2025-12-31","value":-1.08},{"period":"2024-12-31","value":-0.86},{"period":"2023-12-31","value":-1.2},{"period":"2022-12-31","value":-1.57}],"cash":104132000,"cashHistory":[{"period":"2025-12-31","value":104132000},{"period":"2024-12-31","value":227380000},{"period":"2023-12-31","value":239566000},{"period":"2022-12-31","value":382436000}],"totalAssets":589068000,"totalLiabilities":410939000,"totalDebt":71387000,"equity":178129000,"operatingCashflow":-283568000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-283568000},{"period":"2024-12-31","value":-206271000},{"period":"2023-12-31","value":-145587000},{"period":"2022-12-31","value":-112308000}],"capex":-27132000,"capexHistory":[{"period":"2025-12-31","value":-27132000},{"period":"2024-12-31","value":-34819000},{"period":"2023-12-31","value":-10986000},{"period":"2022-12-31","value":-10841000}],"freeCashflow":-310700000,"dividendsPaid":null,"buybacks":null,"employees":752,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":35795000,"ebit":-68679000,"ebitda":-68679000,"period":"2025-12-31","revenue":24289000,"epsBasic":null,"netIncome":-90332000,"rdExpense":35633000,"epsDiluted":null,"grossProfit":-1041000,"operatingIncome":-72469000},{"sga":36280000,"ebit":-68066000,"ebitda":-64703000,"period":"2025-09-30","revenue":21194000,"epsBasic":-0.3,"netIncome":-79118000,"rdExpense":27892000,"epsDiluted":-0.3,"grossProfit":-7449000,"operatingIncome":-71621000},{"sga":30265000,"ebit":-61217000,"ebitda":-56906000,"period":"2025-06-30","revenue":20923000,"epsBasic":-0.18,"netIncome":-47917000,"rdExpense":27430000,"epsDiluted":-0.18,"grossProfit":-3522000,"operatingIncome":-61217000},{"sga":29534000,"ebit":-57793000,"ebitda":-55516000,"period":"2025-03-31","revenue":8982000,"epsBasic":-0.26,"netIncome":-70161000,"rdExpense":26734000,"epsDiluted":-0.26,"grossProfit":-8969000,"operatingIncome":-65237000},{"sga":33676000,"ebit":-56979000,"ebitda":-54902000,"period":"2024-12-31","revenue":29000,"epsBasic":null,"netIncome":-27606000,"rdExpense":30830000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-75864000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.31,"netIncome":null,"rdExpense":null,"epsDiluted":-0.31,"grossProfit":0,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.6,"previousClose":1.71,"fiftyTwoWeekHigh":2.7,"fiftyTwoWeekLow":1.18,"fiftyTwoWeekRange":"1.175 - 2.7","fiftyDayAverage":1.49,"twoHundredDayAverage":1.57,"beta":0,"enterpriseValue":-150133056,"forwardPE":-2.3,"priceToBook":0.27,"priceToSales":394.88,"enterpriseToRevenue":-139.21,"enterpriseToEbitda":2.18,"pegRatio":0,"ebitda":-68942608,"ebitdaMargin":0,"freeCashflow":0,"operatingCashflow":0,"totalDebt":0,"debtToEquity":0,"currentRatio":11.05,"returnOnAssets":-22.3,"returnOnEquity":-29.6,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":8.68,"targetHighPrice":11,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":18.1,"institutionHeldPercent":76.1,"sharesOutstanding":266143286,"floatShares":33904120,"sharesShort":13088539,"shortRatio":9.12,"shortPercentOfFloat":4.9,"epsTrailing":-1.08,"epsForward":-0.71,"revenuePerShare":0.03,"bookValue":5.91,"officers":[{"age":61,"name":"Dr. Christian Martin Itin Ph.D.","title":"CEO & Director"},{"age":53,"name":"Dr. Martin  Pule M.D., MBBS","title":"Founder, Senior VP & Chief Scientific Officer"},{"age":54,"name":"Mr. Robert F. Dolski","title":"Senior VP & CFO"},{"age":60,"name":"Mr. Christopher  Vann","title":"Senior VP & COO"},{"age":45,"name":"Mr. Patrick  McIlvenny","title":"Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer"},{"age":50,"name":"Ms. Miranda  Neville","title":"Senior VP & Chief Technology Officer"},{"age":49,"name":"Mr. Alex  Driggs","title":"Senior VP of Legal Affairs & General Counsel and Secretary"},{"age":60,"name":"Mr. Alexander  Swan","title":"Senior VP & Chief Human Resources Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.autolus.com","phone":"44 20 3829 6230"}}